Frank Greenway
Overview
Explore the profile of Frank Greenway including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Feng B, Harms J, Patel N, Ye H, Luo P, Irizarry V, et al.
Mol Metab
. 2021 Nov;
54():101391.
PMID: 34767997
Objective: Cav3.2, a T-type low voltage-activated calcium channel widely expressed throughout the central nervous system, plays a vital role in neuronal excitability and various physiological functions. However, the effects of...
12.
Karki N, Aggarwal S, Laine R, Greenway F, Losso J
Chem Biol Interact
. 2020 Jul;
327:109142.
PMID: 32610056
Juglone and thymoquinone are cytotoxic to pancreatic cancer cells. The aim of this study was to investigate, using an analysis of isobolograms, the type and degree of interactions between juglone...
13.
Lee M, Kim S, Watkins E, Moon M, Rhee S, Frias J, et al.
J Diabetes Complications
. 2020 Feb;
34(5):107555.
PMID: 32019723
Aim: MLR-1023, called Tolimidone when evaluated unsuccessfully by Pfizer for gastric ulcer disease, has been repurposed as a novel oral insulin sensitizer with its effects mediated by selective activation of...
14.
Brinkley T, Anderson A, Soliman E, Bertoni A, Greenway F, Knowler W, et al.
Am J Hypertens
. 2018 Jan;
31(5):541-548.
PMID: 29324968
Background: Left ventricular hypertrophy assessed by electrocardiography (ECG-LVH) is a marker of subclinical cardiac damage and a strong predictor of cardiovascular disease (CVD) events. The prevalence of ECG-LVH is increased...
15.
Espeland M, Luchsinger J, Baker L, Neiberg R, Kahn S, Arnold S, et al.
Neurology
. 2017 Apr;
88(21):2026-2035.
PMID: 28446656
Objective: To assess whether an average of 10 years of lifestyle intervention designed to reduce weight and increase physical activity lowers the prevalence of cognitive impairment among adults at increased...
16.
le Roux C, Astrup A, Fujioka K, Greenway F, Lau D, Van Gaal L, et al.
Lancet
. 2017 Feb;
389(10077):1399-1409.
PMID: 28237263
Background: Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the...
17.
Fujioka K, ONeil P, Davies M, Greenway F, Lau D, Claudius B, et al.
Obesity (Silver Spring)
. 2016 Nov;
24(11):2278-2288.
PMID: 27804269
Objective: To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early...
18.
Tam C, Redman L, Greenway F, LeBlanc K, Haussmann M, Ravussin E
J Clin Endocrinol Metab
. 2016 Aug;
101(10):3755-3764.
PMID: 27490919
Context: It is not known whether the magnitude of metabolic adaptation, a greater than expected drop in energy expenditure, depends on the type of bariatric surgery and is associated with...
19.
Aryana K, Greenway F, Dhurandhar N, Tulley R, Finley J, Keenan M, et al.
F1000Res
. 2016 Mar;
4:139.
PMID: 26925221
The rising prevalence of obesity and the vulnerability of the pediatric age group have highlighted the critical need for a careful consideration of effective, safe, remedial and preventive dietary interventions. ...
20.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al.
N Engl J Med
. 2015 Jul;
373(1):11-22.
PMID: 26132939
Background: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to...